CTLA4 and cancer: As previously described, the immune checkpoint pathways CTLA4—CD80/CD86 and PD-1—PD-L1 inhibit T cell activation thus maintaining peripheral tolerance and helping cancer cells evade cytotoxic T cell mediated death.